By Scott Roberts
FRIDAY, March 21, 2014 (HealthDay News) -- Otezla (apremilast) has been approved by the U.S. Food and Drug Administration to treat adults with active psoriatic arthritis, a condition associated with the autoimmune skin disease psoriasis.
Otezla was evaluated in clinical studies involving nearly 1,500 people with active psoriatic arthritis. In a Friday news release, the FDA said Otezla users should be monitored carefully for unexplained weight loss or signs of depression. Pregnant women must register for the drug's use, the agency added.
Otezla is produced for Celgene Corp., based in Summit, N.J.